In the exploration of treatments for advanced esophageal squamous cell carcinoma (ESCC), researchers compared outcomes of neoadjuvant chemotherapy (NCT), neoadjuvant chemoradiotherapy (NCRT), and neoadjuvant immunochemotherapy (NICT). NCRT and NICT groups exhibited superior pathological responses, with higher pathologic complete response rates (29.9% and 23.6%, respectively) compared to NCT (8.1%). NCRT significantly reduced lymph node metastasis in specific stations, highlighting its efficacy in select cases. Tailoring neoadjuvant strategies based on tumor characteristics emerges as crucial for optimizing therapeutic responses in ESCC.
Journal Article by Tian Y, Shi Z (…) Chen Y et 7 al. in Ann Surg Oncol
© 2023. Society of Surgical Oncology.